Blog

Molecular profiling of sqNSCLC reveals high incidence of actionable genomic alterations among patients with no history of smoking

Stephen V Liu/X

Jan 22, 2025, 10:25

Molecular profiling of sqNSCLC reveals high incidence of actionable genomic alterations among patients with no history of smoking

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X:

“Comprehensive profiling of sqNSCLC

AGAs were detected in 22.2% of never-smokers

Never-smokers with sqNSCLC had a significantly higher prevalence of actionable MET (9.5% vs 0.4%) and EGFR mutations (7.9% vs 0.4%) compared to ever-smokers.”

Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking

Authors: Joshua E. Reuss, Jacob Zaemes, Nishant Gandhi, Phillip Walker, Sandip P. Patel, Joanne Xiu, Charu Aggarwal, Ari Vanderwalde, Suresh S. Ramalingam, Balazs Halmos, Stephen V. Liu

Molecular profiling of sqNSCLC reveals high incidence of actionable genomic alterations among patients with no history of smoking

Ari Vanderwalde Balazs Halmos cancer Charu Aggarwal Jacob Zaemes Joanne Xiu Joshua E. Reuss Nishant Gandhi OncoDaily Oncology Phillip Walker Sandip P Patel Stephen V Liu Suresh S. Ramalingam Yakup Ergün

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology